Michael D. Krepps.
A poster presenting the final results of an investigator-sponsored study led by Dr. Steven J. Isakoff, MD, Ph.D. (Massachusetts General Hospital) titled: A Phase 1b study of PVX-410 Vaccine in Combination with Pembrolizumab in Metastatic Triple Negative Breast Cancer (mTNBC) was presented at this year’s SABCS.
The study results were presented to over 8,000 conference attendees representing leading academic researchers and clinicians from over 90 countries. Topline data showed PVX-410 plus pembrolizumab is safe with manageable toxicity with no unexpected adverse events in mTNBC patients. Most importantly, the study found that PVX-410 induces antigen-specific T cell expansion with increases in PVX-410 tetramer-positive T cells as well as IFN-positive T cells.
Also shown is a clinical disease control with a Clinical Benefit Rate of 31.6%. Based on these promising immune response results in this pretreated population, a Phase 2 study with PVX-410 in combination with pembrolizumab and chemotherapy in treatment-naïve, PD-L1+ mTNBC is underway (NCT04634747).
The SABCS has brought together an international audience of academic and private physicians and researchers since 1978 to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, and OncoPep is proud to be a part of this prestigious conference.
Poster authors included Aditya Bardia, MD, MPH, Laura Spring, MD, Hannah Park, MPH, and Maya Collins (Massachusetts General Hospital); Nadine M. Tung, MD (Beth Israel Deaconess Medical Center); Jun Yin, MPH, Nabihah Tayob, Ph.D., William T. Barry, Ph.D., Mariano Severgnini, Ph.D., and Sara M. Tolaney, MD (Dana Farber Cancer Institute); Doris Peterkin, MBA (OncoPep) and independent consultants Joanne Parker, Ph.D. and Julie Rosenberg, MD. The study was funded by OncoPep and Merck & Co., Inc.